Breakthrough drug nearly doubles survival with advanced pancreatic cancer – an oncologist explains how daraxonrasib overcame an ‘undruggable’ disease

Image: KRAS Protein Structure. RAS is a family of related proteins that is expressed in all animals. KRAS is one of three RAS genes found in humans. RAS genes are mutated in approximately one-third of all human cancers. Image credit: National Cancer Institute via Unsplash. Article by Christopher Lieu. The Conversation – June 2, 2026.

For a long time, the likelihood of surviving pancreatic cancer has been extremely low. For patients who were diagnosed with metastatic pancreatic cancer between 2015 and 2021, about 97% died within five years of their diagnosis. Pancreatic cancer is so deadly in part because there are no effective screening tests, and it rarely causes noticeable symptoms in its earliest stages. By the time a patient experiences signs, such as jaundice – a yellowing of the skin – or abdominal pain, the cancer has often already spread to other organs. […]

Click here to view original web page at www.theconversation.com

Video: FDA approves groundbreaking new drug for pancreatic cancer – NBC News

Related articles:

How Significant is the Approval of Daraxonrasib in Pancreatic Cancer? – CancerNetwork

Pancreatic cancer drug approved by FDA is “exceptional moment,” Boston researcher says – CBS News

FDA Approves Rasonque for Pancreatic Cancer: When It’s Available and Cost – Newsweek

FDA Approves Revolution-ary New Drug for Pancreatic Cancer – Cancer Health

New FDA-approved drug offers hope in pancreatic cancer treatment – NPR